Healthcare Nanotechnology (Nanomedicine) Market Technological Innovation and Growth 2021: Bristol-Myers Squibb Company, CytImmune Sciences Inc., Johnson & Johnson, Luminex Corporation

Global Healthcare Nanotechnology (Nanomedicine) Market Size, Status and Forecast 2021

The Global Healthcare Nanotechnology (Nanomedicine) Market Research Report 2021-2027 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

The global healthcare nanotechnology (nanomedicine) is projected to register a CAGR of 11.9% over the forecast period, 

Get Free Sample Copy before Purchase:

https://www.marketinsightsreports.com/reports/05202907399/healthcare-nanotechnology-nanomedicine-market-growth-trends-covid-19-impact-and-forecasts-2021-2026/inquiry?Mode=XXII

Market Segmentation:

Key Players:
Sanofi SA, Bristol-Myers Squibb Company, CytImmune Sciences Inc., Johnson & Johnson, Luminex Corporation, Merck & Co. Inc., Nanobiotix, Pfizer Inc., Starpharma Holdings Limited, Taiwan Liposome Company Ltd, Copernicus Therapeutics, Inc. and others.

Neurological Diseases is Expected to Show Better Growth in the Forecast Period

Nanomedicine is a promising mode of cancer treatment. This growing field of medical research can be used to discover the better-personalized treatment for a wide range of diseases, including cancer. Globally, the prevalence of cancer is increasing. For instance, according to the Globocan 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020.?

In the field of oncology, nanomedicine offers promising transformations from the existing methods of treatments and diagnosis of cancer. The adoption of nano-based cancer therapies and diagnostics has witnessed noteworthy progress and numerous new developments are currently in the pipeline.

As per the research article published in the American Chemical Society, a total of 75 cancer nanomedicines were under clinical investigation, as of 2019. Among the ongoing and completed clinical trials, 91 (48 completed) are Phase 1, 78 (59 completed) are Phase 2, and 21 (11 completed) are Phase 3. The success rate of Phase 1 trials has been high (approximately 94%).

Moroever, the frequent launches of cancer medicines pertaining to nanomedicine technology is also driving the market significantly. In April 2019, Nanobiotix, a clinical stage nanomedicine company, obtained the CE approval for its Hensify (NBTXR3), an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into a tumor prior to a patients first standard radiotherapy treatment of advanced soft tissue sarcoma.

According to a research article by Ye Zhang et al., published in Journal of Hematology & Oncology Journal 2019, researchers at Memorial Sloan Kettering Cancer Center and Cornell University developed silica-hybrid nanoparticles (C-dots) for PET imaging of patients with metastatic melanoma or malignant brain tumors. These nanoparticles coupled with 124I-labeled cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides that are able toselectively bind to integrins can be used to probe tumor cells.

Browse Full Report at:

https://www.marketinsightsreports.com/reports/05202907399/healthcare-nanotechnology-nanomedicine-market-growth-trends-covid-19-impact-and-forecasts-2021-2026?Mode=XXII

There are 13 Sections to show the global Healthcare Nanotechnology (Nanomedicine) market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Healthcare Nanotechnology (Nanomedicine) Market Research Findings and Conclusion, Appendix, methodology and data source

Finally, researchers throw light on the pinpoint analysis of Global Healthcare Nanotechnology (Nanomedicine) Market dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. The degree of competition is also measured in the research report. With the help of SWOT and Porter’s five analysis, the market has been deeply analyzed. It also helps to address the risk and challenges in front of the businesses. Furthermore, it offers extensive research on sales approaches.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

CONTACT US:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

ABOUT US:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.